Characteristics (n = 36) | Participants n (%) | |
---|---|---|
Age > 50 years | 27 (76) | |
Cancer type | ||
Breast | 22 (61.2) | |
Breast left | 2 (5.6) | |
Carcinoma of breast (elective (L) mastectomy 4/8/15) | 1 (2.8) | |
Lower-inner quadrant of breast | 1 (2.8) | |
Malignant breast cancer | 1 (2.8) | |
Malignant neoplasm of breast | 3 (8.3) | |
Malignant neoplasm of upper-outer quadrant of breast | 1 (2.8) | |
Metastatic HER-2 pos breast cancer | 1 (2.8) | |
Palpable cancer right breast | 1 (2.8) | |
Missing | 3 (8.3) | |
Chemotherapy | ||
Mean number of chemotherapy cycles 4.9 (Median 3) Range (1–16) | ||
Agent class | Mean Dose (mg) | n (%) |
Alkylating agents | ||
Carboplatin | 658 | 5 (13.8%) |
Cyclophosphamide | 1073 | 20 (56%) |
Anthracyclines | ||
Doxorubicin | 110 | 11 (30%) |
Antimetabolites | ||
Fluorouracil | 996 | 6 (17%) |
Mitotic Inhibitors | ||
Docetaxel | 158 | 15 (42%) |
Paclitaxel | 156 | 20 (56%) |
Monoclonal Antibody | ||
Denosumab | 120 | 1 (2%) |
Trastuzumab | 493 | 13 (36%) |
Baseline Cardiac Assessment | ||
Echocardiography | 14 (38.9) | |
Left Ventricular Ejection Fraction <45% | 0 (0) | |
Angiography | 1 (2.8) | |
Electrocardiogram | 11 (30.6) |